OBJECTIVE: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. METHODS: From Oct. 2003 to Dec. 2005, 75 patients were treated withplatinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). RESULTS: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P=0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P=0.04). CONCLUSION: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.
RCT Entities:
OBJECTIVE: The incidence of anemia in the cervical cancerpatients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancerpatients undergoing concurrent chemoradiotherapy. METHODS: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). RESULTS: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P=0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P=0.04). CONCLUSION: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancerpatients receiving concurrent chemoradiotherapy.
Authors: Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana Journal: Blood Transfus Date: 2013-06-17 Impact factor: 3.443
Authors: J Coussirou; A Debourdeau; A Stancu; C Jean; W Azouza; B Chanet; F De Crozals; R Boustany; P Debourdeau Journal: Support Care Cancer Date: 2018-05-24 Impact factor: 3.603
Authors: Alain Toledano; Elisabeth Luporsi; Jean François Morere; Florian Scotté; Kamel Laribi; Jérôme Barrière; Philippe Huot-Marchand; Ladan Duvillié; Victor Hugo Concas; Roland Bugat Journal: Support Care Cancer Date: 2015-04-29 Impact factor: 3.603
Authors: Julia E Inglis; Po-Ju Lin; Sarah L Kerns; Ian R Kleckner; Amber S Kleckner; Daniel A Castillo; Karen M Mustian; Luke J Peppone Journal: Nutr Cancer Date: 2019-01-26 Impact factor: 2.900
Authors: Manuel Muñoz; Susana Gómez-Ramírez; Martin Besser; José Pavía; Fernando Gomollón; Giancarlo M Liumbruno; Sunil Bhandari; Mercé Cladellas; Aryeh Shander; Michael Auerbach Journal: Blood Transfus Date: 2017-09 Impact factor: 3.443